font size
Sign in 
It’s been a bumpy road for biotech in 2010, but as we head into the home stretch investors are looking at a long list of upcoming events that could spark movement in biotech stocks. We spoke to Adam Feuerstein, senior columnist for TheStreet.com, about his recent Fall Preview for the publication. Feuerstein discusses the ongoing dance between Sanofi and Genzyme, the race for a new obesity drug, and what events are expected to occur before year end that may deliver some punch to the sector. Read More
Deals
- Roche Bets $635 Million on Parkinson's, Alzheimer's Programs
New partnership with Belgium's reMynd targets toxicity. Read More
Legislation
- Obama Calls for a Permanent Extension of the R&D Tax Credit
Life sciences industry groups want it, but venture investors do not. Read More
Regulatory
- Healthcare Reform Expected to Have Moderate Impact on Spending
Cost projected to reach nearly $4.6 trillion by 2019. Read More
Drug Development
- FDA Stays Idenix Hepatitis C Study
Idenix hopes to be back on track by year's end. Read More
Mergers and Acquisitions
- Bristol Courts ZymoGenetics with $885 Million
Acquisition delivers potential hepatitis C blockbuster. Read More
Infectious Disease
- Super Bugs May Hold Key to Fighting Superbugs
Cockroach brains could be rich stores of new antibiotics. Read More
Public Health
- Ghost in the Machine
Study looks at how Wyeth paid writers to insert marketing messages into journal articles. Read More
Government Funding
- Boon for Biodefense
Cellerant and Achaogen rack up millions in new contracts. Read More
Biofuels
- USDA and DOE Fund Biofuel Genomics Research
Grants aim to accelerate development of plants better suited for bioenergy production. Read More
Trials and Tribulations
- Roche Plans Cost-Cutting as It Feels Pressure from Reform, Delays, and Failures
The weekly round-up of failed trials, missed targets and other business mishaps. Read More
- The Burrill Report (September 13, 2010): What's in Store for the 2010 Home Stretch
Listen to the latest edition from The Journal of Life Sciences. Browse all podcasts
Now Available
The Burrill Report
August 2010
August 2010
The August issue of The Burrill Report is now available.
Click here to buy.
Podcast
DOJ Seeks Stay in Stem Cell Ruling
Ken Taymor, executive director of the Berkeley Center for Law, Business and Economy, discusses the Justice Department’s request for a stay on the injunction against federal funding of human embryonic stem cell research.
.jpg)
.jpg)
By the numbers
Genzyme Rejects Sanofi’t $18.5 Billion Takeover Offer
Sanofi-Aventis made a formal offer to acquire Genzyme for $69 per share, an offer that was unanimously rejected by Genzyme’s board of directors as unrealistic and opportunistic.
.jpg)
.gif)
.gif)
.png){kind=small}
- Top Genentech research exec departing for academia
Reuters - Health Plan Won’t Fuel Big Spending, Report Says
The New York Times - Lilly Invests $150 Million With Venture Firms Seeking New Drug Candidates
Bloomberg - Genzyme Investors Push for Sanofi Bid of $75 a Share
Bloomberg - Sanofi's CEO Viehbacher Pitches Genzyme Investors in New York on Takeover
Bloomberg - Valeant, Biovail to cut 25 pct jobs of combined co
Reuters - Elan gets injunction vs directors, slams investor
Reuters - Sanofi Chief Extends Hand to Bypass Genzyme `Brick Wall'
Bloomberg - U.S. Court Rules Against Obama’s Stem Cell Policy
The New York Times - Takeda Says Lifestyle-Disease Drugs Will Drive Growth
Bloomberg